Clearbridge Investments LLC Boosts Stake in Bio-Techne Corporation
May 27, 2023
Trending News ☀️
BIO-TECHNE ($NASDAQ:TECH): Clearbridge Investments LLC has recently boosted their stake in Bio-Techne Corporation, a global life sciences company that develops and manufactures biotechnology reagents and instruments. With a wide range of products, including proteins, antibodies, and testing kits, the company has been providing solutions for research, development, and diagnostic applications worldwide. Through its two segments, Biotechnology and Protein Platforms, the company provides a variety of biological tools and technologies that are being used to unlock the secrets of life and improve the quality of life. Bio-Techne is a leader in the biotech industry and its products are used in a wide range of sectors including pharmaceuticals, biotechnology, diagnostics, life sciences research and development, animal health, forensics, regenerative medicine, and food safety.
The company is committed to driving innovation in these sectors and to creating meaningful solutions for its customers. Clearbridge Investments LLC has made a significant investment in Bio-Techne Corporation, recognizing its potential to be a leading provider of biotechnology solutions. With the increased stake in the company, Clearbridge is looking to capitalize on Bio-Techne’s success in the industry and to benefit from its growth in the foreseeable future.
Stock Price
Clearbridge Investments LLC recently increased their stake in Bio-Techne Corporation, a biotechnology and life sciences company specializing in the development, manufacture, and sale of biotechnology reagents, instruments, and related services. On Thursday, Bio-Techne Corporation’s stock opened at $81.9 and closed at $82.3, marking a 0.7% increase from the last closing price of $81.7. This news was welcomed by investors as it signals a strong outlook for the company. With its wide range of products and services, Bio-Techne Corporation is well-positioned to capitalize on the growing demand for biotechnology solutions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 1.12k | 271.28 | 23.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…
| Operations | Investing | Financing |
| 273.72 | -279.46 | -18.89 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.6k | 710.01 | 11.63 |
Key Ratios Snapshot
Some of the financial key ratios for Bio-techne Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 14.2% | 20.7% | 25.5% |
| FCF Margin | ROE | ROA |
| 20.7% | 9.8% | 6.9% |
Analysis
At GoodWhale, we are here to help you analyze BIO-TECHNE CORPORATION‘s financials and make informed decisions about your investments. After performing an extensive analysis, we have determined that BIO-TECHNE CORPORATION is a high risk investment in terms of financial and business aspects. Our Risk Rating tool has detected 3 risk warnings in the company’s income statement, balance sheet and non-financial information. By signing up with us, you can gain access to our detailed analysis of BIO-TECHNE CORPORATION and get insights into potential risks associated with your investments. We believe that by arming yourself with the necessary information and taking the right steps, you can make sound decisions about your investments and reap rewards in the long run. More…
Peers
In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.
– Proteomics International Laboratories Ltd ($ASX:PIQ)
Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.
– AEterna Zentaris Inc ($TSX:AEZS)
Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.
– AXIM Biotechnologies Inc ($OTCPK:AXIM)
AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.
The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.
The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.
Summary
Clearbridge Investments LLC recently reported an increased stake in Bio-Techne Corporation, a biotech company engaged in the development and production of biotechnology solutions. This new investment is seen as a strong endorsement of the company’s future growth prospects and financial health. Its balance sheet remains healthy, with strong cash balances and low debt levels.
Additionally, Bio-Techne has made strategic investments in its research and development, which should enable the company to remain competitive in the long-term. This strategic investing decision is likely to provide strong returns for investors in the future.
Related Posts
Recent Posts
